Risk of <i>Pneumocystis jirovecii</i> Pneumonia among Solid Organ Transplant Recipients: A Population-Based Study

Few studies have comprehensively investigated the occurrence of <i>Pneumocystis jirovecii</i> pneumonia (PJP) among solid organ transplant (SOT) recipients. This study investigated the risk of PJP after organ transplantation. Each patient who underwent SOT was propensity-score-matched wi...

Full description

Bibliographic Details
Main Authors: Yih-Dih Cheng, Ching-Hua Huang, Shuo-Yan Gau, Ning-Jen Chung, Shiang-Wen Huang, Cheng-Yang Huang, Chien-Ying Lee
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Journal of Fungi
Subjects:
Online Access:https://www.mdpi.com/2309-608X/9/1/23
_version_ 1827624218993360896
author Yih-Dih Cheng
Ching-Hua Huang
Shuo-Yan Gau
Ning-Jen Chung
Shiang-Wen Huang
Cheng-Yang Huang
Chien-Ying Lee
author_facet Yih-Dih Cheng
Ching-Hua Huang
Shuo-Yan Gau
Ning-Jen Chung
Shiang-Wen Huang
Cheng-Yang Huang
Chien-Ying Lee
author_sort Yih-Dih Cheng
collection DOAJ
description Few studies have comprehensively investigated the occurrence of <i>Pneumocystis jirovecii</i> pneumonia (PJP) among solid organ transplant (SOT) recipients. This study investigated the risk of PJP after organ transplantation. Each patient who underwent SOT was propensity-score-matched with four non-SOT individuals in terms of sex, age, insured salary, urbanization of residence, comorbidities, and year of enrollment. When considering the 3-year follow-up, the patients who had undergone SOT were at higher risk of PJP, with the adjusted odds ratio (aOR) being 17.18 (95% confidence interval (CI): 8.80–33.53). Furthermore, SOT recipients were also at higher PJP risk than the patients without SOT at 6 months, 1 year, and 2 years, with the aOR being 22.64 (95% CI: 7.53–68.11), 26.19 (95% CI: 9.89–69.37), and 23.06 (95% CI: 10.23–51.97), respectively. Patients comorbid with HIV infection, hematological malignancies, or vasculitis were at higher risk (aOR = 59.08, 95% CI = 20.30–171.92), (aOR = 11.94, 95% CI = 5.36–26.61), and (aOR = 21.72, 95% CI = 2.41–195.81), respectively. The recipients of SOT were at higher risk of PJP, and PJP can develop at any stage after transplantation. SOT recipients comorbid with HIV, hematologic malignancies, or vasculitis were at higher PJP risk.
first_indexed 2024-03-09T12:04:48Z
format Article
id doaj.art-837aead16bf74f36b142ea96d1291d00
institution Directory Open Access Journal
issn 2309-608X
language English
last_indexed 2024-03-09T12:04:48Z
publishDate 2022-12-01
publisher MDPI AG
record_format Article
series Journal of Fungi
spelling doaj.art-837aead16bf74f36b142ea96d1291d002023-11-30T22:59:17ZengMDPI AGJournal of Fungi2309-608X2022-12-01912310.3390/jof9010023Risk of <i>Pneumocystis jirovecii</i> Pneumonia among Solid Organ Transplant Recipients: A Population-Based StudyYih-Dih Cheng0Ching-Hua Huang1Shuo-Yan Gau2Ning-Jen Chung3Shiang-Wen Huang4Cheng-Yang Huang5Chien-Ying Lee6School of Pharmacy, China Medical University, Taichung 40402, TaiwanDepartment of Pharmacology, Chung Shan Medical University, Taichung 40201, TaiwanSchool of Medicine, Chung Shan Medical University, Taichung 40201, TaiwanSchool of Medicine, Chung Shan Medical University, Taichung 40201, TaiwanSchool of Medicine, Chung Shan Medical University, Taichung 40201, TaiwanSchool of Medicine, Chung Shan Medical University, Taichung 40201, TaiwanDepartment of Pharmacology, Chung Shan Medical University, Taichung 40201, TaiwanFew studies have comprehensively investigated the occurrence of <i>Pneumocystis jirovecii</i> pneumonia (PJP) among solid organ transplant (SOT) recipients. This study investigated the risk of PJP after organ transplantation. Each patient who underwent SOT was propensity-score-matched with four non-SOT individuals in terms of sex, age, insured salary, urbanization of residence, comorbidities, and year of enrollment. When considering the 3-year follow-up, the patients who had undergone SOT were at higher risk of PJP, with the adjusted odds ratio (aOR) being 17.18 (95% confidence interval (CI): 8.80–33.53). Furthermore, SOT recipients were also at higher PJP risk than the patients without SOT at 6 months, 1 year, and 2 years, with the aOR being 22.64 (95% CI: 7.53–68.11), 26.19 (95% CI: 9.89–69.37), and 23.06 (95% CI: 10.23–51.97), respectively. Patients comorbid with HIV infection, hematological malignancies, or vasculitis were at higher risk (aOR = 59.08, 95% CI = 20.30–171.92), (aOR = 11.94, 95% CI = 5.36–26.61), and (aOR = 21.72, 95% CI = 2.41–195.81), respectively. The recipients of SOT were at higher risk of PJP, and PJP can develop at any stage after transplantation. SOT recipients comorbid with HIV, hematologic malignancies, or vasculitis were at higher PJP risk.https://www.mdpi.com/2309-608X/9/1/23<i>Pneumocystis jirovecii</i> pneumoniasolid organ transplantadjusted odds ratio
spellingShingle Yih-Dih Cheng
Ching-Hua Huang
Shuo-Yan Gau
Ning-Jen Chung
Shiang-Wen Huang
Cheng-Yang Huang
Chien-Ying Lee
Risk of <i>Pneumocystis jirovecii</i> Pneumonia among Solid Organ Transplant Recipients: A Population-Based Study
Journal of Fungi
<i>Pneumocystis jirovecii</i> pneumonia
solid organ transplant
adjusted odds ratio
title Risk of <i>Pneumocystis jirovecii</i> Pneumonia among Solid Organ Transplant Recipients: A Population-Based Study
title_full Risk of <i>Pneumocystis jirovecii</i> Pneumonia among Solid Organ Transplant Recipients: A Population-Based Study
title_fullStr Risk of <i>Pneumocystis jirovecii</i> Pneumonia among Solid Organ Transplant Recipients: A Population-Based Study
title_full_unstemmed Risk of <i>Pneumocystis jirovecii</i> Pneumonia among Solid Organ Transplant Recipients: A Population-Based Study
title_short Risk of <i>Pneumocystis jirovecii</i> Pneumonia among Solid Organ Transplant Recipients: A Population-Based Study
title_sort risk of i pneumocystis jirovecii i pneumonia among solid organ transplant recipients a population based study
topic <i>Pneumocystis jirovecii</i> pneumonia
solid organ transplant
adjusted odds ratio
url https://www.mdpi.com/2309-608X/9/1/23
work_keys_str_mv AT yihdihcheng riskofipneumocystisjiroveciiipneumoniaamongsolidorgantransplantrecipientsapopulationbasedstudy
AT chinghuahuang riskofipneumocystisjiroveciiipneumoniaamongsolidorgantransplantrecipientsapopulationbasedstudy
AT shuoyangau riskofipneumocystisjiroveciiipneumoniaamongsolidorgantransplantrecipientsapopulationbasedstudy
AT ningjenchung riskofipneumocystisjiroveciiipneumoniaamongsolidorgantransplantrecipientsapopulationbasedstudy
AT shiangwenhuang riskofipneumocystisjiroveciiipneumoniaamongsolidorgantransplantrecipientsapopulationbasedstudy
AT chengyanghuang riskofipneumocystisjiroveciiipneumoniaamongsolidorgantransplantrecipientsapopulationbasedstudy
AT chienyinglee riskofipneumocystisjiroveciiipneumoniaamongsolidorgantransplantrecipientsapopulationbasedstudy